Mavyret and Chronic obstructive pulmonary disease - a phase IV clinical study of FDA data

Summary:

Chronic obstructive pulmonary disease is reported as a side effect among people who take Mavyret (glecaprevir; pibrentasvir), especially for people who are male, 50-59 old, have been taking the drug for 1 - 6 months also take Amlodipine, and have Hepatitis c.

The phase IV clinical study analyzes which people have Chronic obstructive pulmonary disease when taking Mavyret. It is created by eHealthMe based on reports of 10,526 people who have side effects when taking Mavyret from the FDA, and is updated regularly.

What is Mavyret?

Mavyret has active ingredients of glecaprevir; pibrentasvir. eHealthMe is studying from 10,533 Mavyret users. Check the latest studies of Mavyret.

What is Chronic obstructive pulmonary disease?

Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe) is found to be associated with 1,799 drugs and 2,209 conditions by eHealthMe. Check the latest studies of Chronic obstructive pulmonary disease.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Jul, 30, 2026

10,526 people reported to have side effects when taking Mavyret.
Among them, 38 people (0.36%) have Chronic obstructive pulmonary disease.

Could Mavyret cause Chronic obstructive pulmonary disease?

Among these 38 people:

How long have people been on Mavyret when they have Chronic obstructive pulmonary disease? *

What is the gender of people who have Chronic obstructive pulmonary disease when taking Mavyret? *

female: 48.65 %
male: 51.35 %

What is the age of people who have Chronic obstructive pulmonary disease when taking Mavyret? *

What are other drugs people take besides Mavyret? *

What are other side effects people have besides Chronic obstructive pulmonary disease? *

Dyspnea (difficult or laboured breathing): 6 people, 15.79%
Diarrhea: 4 people, 10.53%
Electrocardiogram Qt Prolonged: 3 people, 7.89%
Stress And Anxiety: 3 people, 7.89%
Rhinovirus Infection: 3 people, 7.89%
Myasthenia Gravis (a chronic condition that causes muscles to tire and weaken easily): 3 people, 7.89%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 3 people, 7.89%
Pneumonia: 3 people, 7.89%
Periarthritis (inflammation of the external coats of an artery and of the tissues around the artery): 2 people, 5.26%
Oxygen Saturation Decreased: 2 people, 5.26%

What are the existing conditions these people have? *

Hepatitis C: 20 people, 52.63%
High Blood Pressure: 4 people, 10.53%
Stress And Anxiety: 3 people, 7.89%
Cardiac Disorder: 3 people, 7.89%
Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs): 2 people, 5.26%
Sleep Disorder: 1 person, 2.63%
Osteoporosis (bones weak and more likely to break): 1 person, 2.63%
Migraine (headache): 1 person, 2.63%
Irritable Bowel Syndrome: 1 person, 2.63%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 2.63%

* Approximation only. Some reports may have incomplete information.

Do you take Mavyret and have Chronic obstructive pulmonary disease?

- Check whether Chronic obstructive pulmonary disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Mavyret:

Mavyret (10,533 reports)

Browse all side effects of Mavyret:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Chronic obstructive pulmonary disease:

Chronic obstructive pulmonary disease (1,799 drugs)

Browse all the conditions that are associated with Chronic obstructive pulmonary disease:

Chronic obstructive pulmonary disease (2,209 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on glecaprevir; pibrentasvir (the active ingredients of Mavyret) and Mavyret (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.